A Study of Combining Talimogene Laherparepvec (T-VEC) and MK-3475 (pembrolizumab) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy (S1607)

A Study of Combining Talimogene Laherparepvec (T-VEC) and MK-3475 (pembrolizumab) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy (S1607)

Trial Category:
Melanoma
Phase
II
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Faith Regional Health System, Carson Cancer Center, Norfolk, NE
Great Plains Health, Callahan Cancer Center, North Platte, NE
Nebraska Cancer Specialists, Omaha, NE
Nebraska Hematology Oncology, Lincoln, NE
Regional West Health Services, Cancer Center, Scottsbluff, NE
Southeast Nebraska Cancer Center, Lincoln, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members